The race to develop CAR T and related cell therapies into a pillar of cancer care is just starting, according to Jay Bradner, president of the Novartis Institutes for BioMedical Research. He’s concerned that the pace is too slow, and that money and scientific resources are being poured into attempts to make incremental progress at a time when there is an urgent need for disruptive change.
Disruption may come from Asia, Bradner told BioCentury, as the advent of CAR T as a commercially viable modality has coincided with the rise of China as a biomedical research engine.
Regulatory innovation, especially around comparability standards to support improvements in manufacturing technologies, is needed to advance the field, Bradner believes. His view is shared by CAR T pioneers from academia, industry and FDA (see “CAR T Developers Plan Steps to Reach More Indications”).